Acute myeloid leukemia (AML) is a hematological tumor characterized by an alteration of the normal maturation process of myeloid precursor cells, leading to leukocytosis and bone marrow failure. Hematopoietic cell transplantation (HCT) is the standard of care for relapsed or refractory pediatric AML patients, but relapse still occur in 40% of them. Therefore, an unmet need to improve therapy is required. My PhD project focuses on the development of a new therapy based on the use of gene modified cord blood (CB) T cells. Our ultimate goal is to potentiate the HCT with CB-T cells specific for AML antigen, in order to target remained lymphoblasts and prevent early relapse.